News

While no significant difference in overall survival benefit between the treatment groups was observed, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

The investigational agent glofitamab produced high responder rates in combination with obinutuzumab in multiple relapsed or refractory follicular lymphoma.

The novel non-covalent BTK inhibitor pirtobrutinib has shown encouraging preclinical efficacy in addressing resistance to ibrutinib and venetoclax resistance in mantle cell lymphoma models cell lines.

Retrospective data from tafasitamab plus lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma correlate with real-world findings.

Based on findings from extended follow-up analysis of the phase 2 ELARA study, tisagenlecleucel is a beneficial treatment for patients with relapsed or refractory follicular lymphoma.

Monsunetuzumab induced deep and durable remission in patients with heavily pretreated follicular lymphoma.

Based on updated findings from the phase 2 SUMMIT trial, a neratinib triplet and neratinib doublet can induce responses in patients with HER2-positive breast cancer.

The combination of obinutuzumab with polatuzumab vedotin, or lenalidomide may be a solution for the toxicity sometimes observed with chimeric antigen receptor T cells in patients with follicular lymphoma.

Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.

The Ocomine Dx Target Test is now FDA-approved to help identify eligible patients to be treated with amivantamab.

Adding zanidatamab to chemotherapy may result in positive efficacy and safety outcomes in patients with HER2-positive breast cancer.

The ability to prolong central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer has been demonstrated in an early clinical trial.

BOVen was found to induce MRD and to have a tolerable safety profile.

The application for poziotinib is supported by the phase 2 ZENITH20 trial. The agent showed a promising safety profile and antitumor activity.

Andrea Moreira, MD, a board-certified plastic surgeon specializing in the use of advanced techniques in breast reconstruction, has joined Allegheny Health Network.

Jill Dietz, MD, FACS, a nationally recognized breast surgeon and leader in the development of innovative, recently joined Allegheny Health Network Cancer Institute.

David L. Bartlett, MD, a renowned cancer researcher and clinician specializing in advanced surgical treatments for abdominal cancers, has reopened his Pittsburgh practice.

In the phase 3 FOCUS study, a positive result for a secondary end point was observed with melphalan hydrochloride for injection in patients with liver-dominant metastatic ocular melanoma.

ST101, an agent being investigated in a phase 1/2 clinical trial, has been granted fast track designation from the FDA for the treatment of patients with glioblastoma multiforme.

Navel G. Daver, MD, discusses the molecular characteristics of acute myeloid leukemia, agents available for the treatment of mutated acute myeloid leukemia, and how to potentially improve treatment in the future.

The post-marketing requirements for duvelisib are no longer necessary, according to the FDA, and the agent has been withdrawn from the United States market for the treatment of patients with relapsed or refractory follicular lymphoma.

Shaakir Hasan, DO, discusses for potential reasons for continuing racial disparities in bladder cancer despite years of evidence of the issue.

In an interview with Targeted Oncology, James M. Foran, MD discussed how recent research has caused a paradigm shift in AML, and which ongoing clinical trials have the potential to change treatment in the near future.

Pembrolizumab for stage IIB or IIC melanoma has been granted approval by the FDA.

In the phase 3 ARASENS study, the use of darolutamide with docetaxel and androgen deprivation therapy demonstrated an overall survival advantage for patients with metastatic hormone-sensitive prostate cancer.

The device is meant to not only target metastatic bone lesions, but also promote the growth of healthy bone.

Luspatercept-aamt for the treatment of anemia in adult patients with non-transfusion dependent beta thalassemia is on track to receive an FDA approval indication.

Elisabetta Abruzzese, MD of S. Eugenio Hospital, discusses the management of pregnancy in patient with chronic myeloid leukemia.

The incidence of adverse events appeared to increase when bendamustine was added to venetoclax for the treatment of patients with released or refractory chronic lymphocytic leukemia

In an interview with Targeted Oncology, lead author Xichun Hu, MD, PhD, discussed A166 and its impact on HER2-positive breast cancer.